169590-41-4 Usage
Description
Deracoxib, a member of the pyrazole class, is a non-steroidal anti-inflammatory drug (NSAID) belonging to the coxib class. It is a selective cyclooxygenase-2 (COX-2) inhibitor characterized by its 1H-pyrazole structure, which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl, and 3-fluoro-4-methoxyphenyl groups, respectively. Deracoxib is primarily used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs.
Uses
Used in Veterinary Medicine:
Deracoxib is used as an anti-inflammatory agent for the treatment of osteoarthritis in dogs. It acts as a selective COX-2 inhibitor, helping to control pain and inflammation without causing significant gastrointestinal side effects at low doses.
Used in Pain Management:
In addition to its use in treating osteoarthritis, Deracoxib is also utilized for managing pain in dogs. Its selective COX-2 inhibition allows for effective pain relief with a lower risk of gastrointestinal complications compared to some other NSAIDs.
Used in Inflammation Control:
Deracoxib is employed as an inflammation control agent, helping to reduce the inflammation associated with various conditions in dogs. Its selective COX-2 inhibition makes it a suitable choice for controlling inflammation while minimizing potential side effects.
Veterinary Drugs and Treatments
Deracoxib is indicated for the treatment of post-operative pain
(higher dose, 7 day maximum), and for the treatment of pain and
inflammation associated with osteoarthritis (lower dose, ongoing
dosing) in dogs.
Like piroxicam, deracoxib is of interest in adjunctive treatment
of transitional cell carcinoma of the bladder; investigations into this
use are ongoing.
Check Digit Verification of cas no
The CAS Registry Mumber 169590-41-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,5,9 and 0 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 169590-41:
(8*1)+(7*6)+(6*9)+(5*5)+(4*9)+(3*0)+(2*4)+(1*1)=174
174 % 10 = 4
So 169590-41-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)
169590-41-4Relevant articles and documents
Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib
Wan, Chao,Pang, Jian-Yu,Jiang, Wei,Zhang, Xiao-Wei,Hu, Xiang-Guo
, p. 4557 - 4566 (2021/03/01)
We have identified a new reactivity of copper/diamine catalysis for the reductive ring-cleavage of isoxazoles to yield fluoroalkylated enaminones. This protocol has the advantage of using commercially available reagents, ease of setting up, broad tolerance of functionality, and is regiospecific and free of defluorination and reduction of reducible functional groups. The utility was demonstrated by a one-step, regioselective synthesis of fluoroalkylated pyrazole-based drugs such as celecoxib, deracoxib, and mavacoxib.
COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR
-
, (2008/06/13)
The present invention provides a combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor for the treatment or prevention of pain or nociception.
Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
-
, (2008/06/13)
This invention relates to the use of a tocolytic agent or agents in combination with selective cyclooxygenase-2 inhibitors of Formula (II) or a pharmaceutically-acceptable salt or derivative thereof for preparing a medicament for maintaining circulation through fetal ductus arteriosus during treatment or prevention of preterm labor in a subject in need of such treatment or prevention.
